Can Prigrel be viable in anti-clotting market?

Sanofi Aventis’s Plavix is truly far ahead of Korea generic markers in the domestic anti-clotting market in terms of market share, however, Chong Kun Dang Pharmaceutical is hoping to challenge its competitors with its chemically modified clopidogrel “Since Prigrel is more cost-effective than our competitors, we will see an increase of prescriptions for the medicine,’’ said a spokesman of Chong ...